Claims
- 1. A method of inducing low density lipoprotein receptor expression through the sole activation of extracellular-signal regulated kinase (p42/44MAPK), comprising the step of:
contacting a cell with a compound that activates the extracellular-signal regulated kinase, p42/44MAPK, wherein the activation of said kinase results in the induction of low density lipoprotein receptor expression.
- 2. The method of claim 1, wherein said induction of low density lipoprotein receptor expression is independent of cell growth regulation.
- 3. The method of claim 1, wherein the extent of said induction of low density lipoprotein receptor expression is dependent on the extent of activation of p42/44MAPK.
- 4. A method of screening a candidate compound that induces p42/44MAPK-mediated LDL receptor expression, comprising the steps of:
contacting a cell that activates p42/44MAPK in response to extracellular stimulant with said candidate compound; and measuring the activation of p42/44MAPK and low density lipoprotein receptor expression, wherein activation of p42/44MAPK and induction of low density lipoprotein receptor expression in the presence of said compound is indicative of said candidate compound can induce p42/44MAPK-mediated low density lipoprotein receptor expression.
- 5. The method of claim 4, wherein said cell is HepG2-ΔRaf-1:ER cell line.
- 6. A method of determining the level of low density lipoprotein receptor expression in an individual, comprising the step of:
examining the level of p42/44MAPK expression in said individual, wherein high p42/44MAPK expression is indicative of high low density lipoprotein receptor expression, and low p42/44MAPK expression is indicative of low low density lipoprotein receptor expression in said individual.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This non-provisional patent application claims benefit of U.S. Ser. No. 60/229,271, filed Aug. 30, 2000, now abandoned.
FEDERAL FUNDING LEGEND
[0002] This invention was produced in part using funds obtained through a grant from the National Institutes of Health. Consequently, the federal government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60229271 |
Aug 2000 |
US |